Department of Laboratory Medicine, Boston Children's Hospital, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
JAMA Cardiol. 2019 Feb 1;4(2):144-152. doi: 10.1001/jamacardio.2018.4635.
Increased free thyroxine (FT4) and decreased thyrotropin are associated with increased risk of atrial fibrillation (AF) in observational studies, but direct involvement is unclear.
To evaluate the potential direct involvement of thyroid traits on AF.
DESIGN, SETTING, AND PARTICIPANTS: Study-level mendelian randomization (MR) included 11 studies, and summary-level MR included 55 114 AF cases and 482 295 referents, all of European ancestry.
Genomewide significant variants were used as instruments for standardized FT4 and thyrotropin levels within the reference range, standardized triiodothyronine (FT3):FT4 ratio, hypothyroidism, standardized thyroid peroxidase antibody levels, and hyperthyroidism. Mendelian randomization used genetic risk scores in study-level analysis or individual single-nucleotide polymorphisms in 2-sample MR for the summary-level data.
Prevalent and incident AF.
The study-level analysis included 7679 individuals with AF and 49 233 referents (mean age [standard error], 62 [3] years; 15 859 men [29.7%]). In study-level random-effects meta-analysis, the pooled hazard ratio of FT4 levels (nanograms per deciliter) for incident AF was 1.55 (95% CI, 1.09-2.20; P = .02; I2 = 76%) and the pooled odds ratio (OR) for prevalent AF was 2.80 (95% CI, 1.41-5.54; P = .003; I2 = 64%) in multivariable-adjusted analyses. The FT4 genetic risk score was associated with an increase in FT4 by 0.082 SD (standard error, 0.007; P < .001) but not with incident AF (risk ratio, 0.84; 95% CI, 0.62-1.14; P = .27) or prevalent AF (OR, 1.32; 95% CI, 0.64-2.73; P = .46). Similarly, in summary-level inverse-variance weighted random-effects MR, gene-based FT4 within the reference range was not associated with AF (OR, 1.01; 95% CI, 0.89-1.14; P = .88). However, gene-based increased FT3:FT4 ratio, increased thyrotropin within the reference range, and hypothyroidism were associated with AF with inverse-variance weighted random-effects OR of 1.33 (95% CI, 1.08-1.63; P = .006), 0.88 (95% CI, 0.84-0.92; P < .001), and 0.94 (95% CI, 0.90-0.99; P = .009), respectively, and robust to tests of horizontal pleiotropy. However, the subset of hypothyroidism single-nucleotide polymorphisms involved in autoimmunity and thyroid peroxidase antibodies levels were not associated with AF. Gene-based hyperthyroidism was associated with AF with MR-Egger OR of 1.31 (95% CI, 1.05-1.63; P = .02) with evidence of horizontal pleiotropy (P = .045).
Genetically increased FT3:FT4 ratio and hyperthyroidism, but not FT4 within the reference range, were associated with increased AF, and increased thyrotropin within the reference range and hypothyroidism were associated with decreased AF, supporting a pathway involving the pituitary-thyroid-cardiac axis.
在观察性研究中,游离甲状腺素(FT4)增加和促甲状腺素降低与心房颤动(AF)风险增加相关,但直接参与机制尚不清楚。
评估甲状腺特征对 AF 的潜在直接影响。
设计、地点和参与者:研究水平的孟德尔随机化(MR)包括 11 项研究,汇总水平的 MR 包括 55114 例 AF 病例和 482295 名对照,均为欧洲血统。
在参考范围内,使用全基因组显著变异作为标准化 FT4 和促甲状腺素水平、标准化三碘甲状腺原氨酸(FT3):FT4 比值、甲状腺功能减退症、标准化甲状腺过氧化物酶抗体水平和甲状腺功能亢进症的工具。在研究水平分析中,孟德尔随机化使用遗传风险评分,或在汇总水平数据的 2 样本 MR 中使用个体单核苷酸多态性。
现患和新发 AF。
研究水平分析包括 7679 例 AF 患者和 49233 名对照(平均年龄[标准误差],62[3]岁;15859 名男性[29.7%])。在研究水平的随机效应荟萃分析中,FT4 水平(纳克/分升)的新发 AF 风险比为 1.55(95%CI,1.09-2.20;P=0.02;I2=76%),多变量调整分析中现患 AF 的比值比为 2.80(95%CI,1.41-5.54;P=0.003;I2=64%)。FT4 遗传风险评分与 FT4 增加 0.082 SD(标准误差,0.007;P<0.001)相关,但与新发 AF(风险比,0.84;95%CI,0.62-1.14;P=0.27)或现患 AF(比值比,1.32;95%CI,0.64-2.73;P=0.46)无关。同样,在汇总水平的逆方差加权随机效应 MR 中,参考范围内的基因 FT4 与 AF 无关(比值比,1.01;95%CI,0.89-1.14;P=0.88)。然而,基于基因的 FT3:FT4 比值升高、参考范围内的促甲状腺素升高和甲状腺功能减退症与基于基因的 FT3:FT4 比值升高、参考范围内的促甲状腺素升高和甲状腺功能减退症相关,其逆方差加权随机效应比值比分别为 1.33(95%CI,1.08-1.63;P=0.006)、0.88(95%CI,0.84-0.92;P<0.001)和 0.94(95%CI,0.90-0.99;P=0.009),且对水平性混杂的检验具有稳健性。然而,涉及自身免疫和甲状腺过氧化物酶抗体水平的甲状腺功能减退症单核苷酸多态性亚组与 AF 无关。基于基因的甲状腺功能亢进症与 AF 相关,MR-Egger 比值比为 1.31(95%CI,1.05-1.63;P=0.02),存在水平性混杂的证据(P=0.045)。
升高的 FT3:FT4 比值和甲状腺功能亢进症(但非参考范围内的 FT4)与 AF 风险增加相关,参考范围内的促甲状腺素升高和甲状腺功能减退症与 AF 风险降低相关,支持涉及垂体-甲状腺-心脏轴的途径。